Cargando…

Cudraflavone B induces human glioblastoma cells apoptosis via ER stress-induced autophagy

BACKGROUND: Glioblastoma (GBM) is the most common malignant intracranial tumor with a low survival rate. However, only few drugs responsible for GBM therpies, hence new drug development for it is highly required. The natural product Cudraflavone B (CUB) has been reported to potentially kill a variet...

Descripción completa

Detalles Bibliográficos
Autores principales: Pan, Jinlin, Zhao, Rongchuan, Dong, Caihua, Yang, Jiao, Zhang, Ruobing, Sun, Minxuan, Ahmad, Nafees, Zhou, Yuanshuai, Liu, Yanxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890863/
https://www.ncbi.nlm.nih.gov/pubmed/36721107
http://dx.doi.org/10.1186/s12868-023-00778-4
Descripción
Sumario:BACKGROUND: Glioblastoma (GBM) is the most common malignant intracranial tumor with a low survival rate. However, only few drugs responsible for GBM therpies, hence new drug development for it is highly required. The natural product Cudraflavone B (CUB) has been reported to potentially kill a variety of tumor cells. Currently, its anit-cancer effect on GBM still remains unknown. Herein, we investigated whether CUB could affect the proliferation and apoptosis of GBM cells to show anti-GBM potential. RESULTS: CUB selectively inhibited cell viability and induced cell apoptosis by activating the endoplasmic reticulum stress (ER stress) related pathway, as well as harnessing the autophagy-related PI3K/mTOR/LC3B signaling pathway. Typical morphological changes of autophagy were also observed in CUB treated cells by microscope and scanning electron microscope (SEM) examination. 4-Phenylbutyric acid (4-PBA), an ER stress inhibitor, restored the CUB-caused alteration in signaling pathway and morphological change. CONCLUSIONS: Our finding suggests that CUB impaired cell growth and induced cell apoptosis of glioblastoma through ER stress and autophagy-related signaling pathways, and it might be an attractive drug for treatment of GBM. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12868-023-00778-4.